SI2542535T1 - Kristalinične oblike natrijeve soli 5-amino-2,3-dihidroftalazin-1,4-diona, farmacevtski pripravki, ki jih vsebujejo, in postopek za njihovo pripravo - Google Patents
Kristalinične oblike natrijeve soli 5-amino-2,3-dihidroftalazin-1,4-diona, farmacevtski pripravki, ki jih vsebujejo, in postopek za njihovo pripravoInfo
- Publication number
- SI2542535T1 SI2542535T1 SI201130233T SI201130233T SI2542535T1 SI 2542535 T1 SI2542535 T1 SI 2542535T1 SI 201130233 T SI201130233 T SI 201130233T SI 201130233 T SI201130233 T SI 201130233T SI 2542535 T1 SI2542535 T1 SI 2542535T1
- Authority
- SI
- Slovenia
- Prior art keywords
- forms
- dihydrophthalazine
- amino
- production
- sodium salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10002067 | 2010-03-01 | ||
| EP10075744 | 2010-11-25 | ||
| EP11710423.2A EP2542535B1 (de) | 2010-03-01 | 2011-03-01 | Kristalline formen von 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung |
| PCT/EP2011/001124 WO2011107295A1 (de) | 2010-03-01 | 2011-03-01 | Kristalline formen zu 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2542535T1 true SI2542535T1 (sl) | 2014-09-30 |
Family
ID=43828190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201130233T SI2542535T1 (sl) | 2010-03-01 | 2011-03-01 | Kristalinične oblike natrijeve soli 5-amino-2,3-dihidroftalazin-1,4-diona, farmacevtski pripravki, ki jih vsebujejo, in postopek za njihovo pripravo |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8772294B2 (sl) |
| EP (2) | EP2774920A1 (sl) |
| JP (2) | JP6061081B2 (sl) |
| KR (1) | KR101770011B1 (sl) |
| CN (3) | CN102971300B (sl) |
| AU (1) | AU2011223226B2 (sl) |
| BR (1) | BR112012021857B1 (sl) |
| CA (1) | CA2791327C (sl) |
| CH (1) | CH704794B1 (sl) |
| CY (1) | CY1115585T1 (sl) |
| DK (1) | DK2542535T3 (sl) |
| ES (1) | ES2487221T3 (sl) |
| HK (2) | HK1223929A1 (sl) |
| HR (1) | HRP20140752T1 (sl) |
| IL (1) | IL221680A (sl) |
| NZ (1) | NZ601689A (sl) |
| PL (1) | PL2542535T3 (sl) |
| PT (1) | PT2542535E (sl) |
| RS (1) | RS53492B1 (sl) |
| RU (1) | RU2585677C2 (sl) |
| SI (1) | SI2542535T1 (sl) |
| WO (1) | WO2011107295A1 (sl) |
| ZA (1) | ZA201206264B (sl) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6061081B2 (ja) | 2010-03-01 | 2017-01-18 | メトリオファーム アーゲー | ５−アミノ−２，３−ジヒドロフタラジン−１，４−ジオンナトリウム塩の結晶形ｉまたはｉｉ、それを含有する医薬品調製物、５−アミノ−２，３−ジヒドロフタラジン−１，４−ジオンナトリウム塩の結晶形ｉの製造方法、および５−アミノ−２，３−ジヒドロフタラジン−１，４−ジオンナトリウム塩の結晶形ｉｉの製造方法 |
| EP3233807B1 (de) | 2014-12-18 | 2019-09-04 | MetrioPharm AG | Kristalline form von 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung |
| CA3011767C (en) | 2016-02-16 | 2024-02-06 | Metriopharm Ag | Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione |
| CN109071461B (zh) * | 2016-02-16 | 2022-06-21 | 麦翠奥制药公司 | 制备5-氨基-2,3-二氢酞嗪-1,4-二酮结晶体的方法 |
| EP3248602A1 (en) | 2016-05-26 | 2017-11-29 | MetrioPharm AG | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae |
| RU2625267C1 (ru) * | 2016-09-22 | 2017-07-12 | Общество с ограниченной ответственностью "АБИДАФАРМА" | Способ производства нестерильных субстанций безводного "тамерита" и/или двухводного "галавита" - натриевых солей 5-амино-2,3-дигидрофталазин-1,4-диона (варианты) и способы дальнейшей их переработки в стерильные лекарственные препараты |
| DK3534904T3 (da) * | 2016-11-07 | 2022-04-11 | Metriopharm Ag | Anvendelse af 5-amino-2,3-dihydro-1,4-phthalazindion i behandlingen af kronisk progressiv multipel sklerose |
| CN106810501B (zh) * | 2017-01-23 | 2019-09-10 | 湖北新德晟材料科技有限公司 | 一种利用一锅法合成鲁米诺或异鲁米诺的方法 |
| RU2635769C1 (ru) * | 2017-02-08 | 2017-11-15 | Адмир Мусаевич Абидов | Лекарственный препарат на основе 5-амино-2,3-дигидрофталазин-1,4-диона в виде быстрорастворимой пленки для трансбуккального введения |
| RU2673452C1 (ru) * | 2017-08-15 | 2018-11-27 | Межрегиональное общественное учреждение "Институт инженерной физики" | Способ получения активной фармацевтической субстанции, представляющей собой аминодигидрофталазиндион натрия |
| EP3511325A1 (en) | 2018-01-11 | 2019-07-17 | MetrioPharm AG | Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione |
| WO2020084348A1 (en) * | 2018-10-26 | 2020-04-30 | Immunopharma Plus D.O.O. | Oral aminodihydrophthalazinedione compositions and their use the treatment of non-viral hepatitis |
| EP3858328A1 (en) | 2020-01-31 | 2021-08-04 | MetrioPharm AG | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the inhalatory treatment of inflammatory pulmonary diseases |
| EP3858358A1 (en) | 2020-01-31 | 2021-08-04 | MetrioPharm AG | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases |
| EP4125802A1 (en) | 2020-03-25 | 2023-02-08 | MetrioPharm AG | 5-amino-2,3-dihydro-1,4-phthalazinedione for treatment of acute lung injury |
| JP2023529022A (ja) | 2020-06-10 | 2023-07-06 | メトリオファーム アーゲー | コロナウイルス感染症の治療のための化合物 |
| EP3981405A1 (en) | 2020-10-08 | 2022-04-13 | MetrioPharm AG | Compound for the treatment of coronaviral infections |
| AU2021304254A1 (en) | 2020-07-09 | 2023-02-16 | Metriopharm Ag | Glucocorticoid-sparing agent |
| CA3199912A1 (en) | 2020-12-02 | 2022-06-09 | Wolfgang Brysch | Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection |
| RU2756568C1 (ru) * | 2021-03-24 | 2021-10-01 | Акционерное общество "Щелково Агрохим" | Способ получения натриевой соли 5-амино-2,3-дигидро-1,4-фталазиндиона в гидратированной или безводной форме |
| EP4193994A1 (en) | 2021-12-08 | 2023-06-14 | MetrioPharm AG | Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a 6'-methoxycinchonan-9-ol for use in the treatment of coronaviral infections |
| EP4209219A1 (en) | 2022-01-07 | 2023-07-12 | MetrioPharm AG | Combination of budesonide and 5-amino-2,3-dihydro-1,4-phtalazinedione |
| EP4248963A1 (en) | 2022-03-25 | 2023-09-27 | MetrioPharm AG | Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a fumaric acid ester |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1089086C (zh) * | 1988-03-31 | 2002-08-14 | 兰德尔·L·米尔斯 | 鲁米纳得类药物 |
| CH683965A5 (it) | 1993-02-19 | 1994-06-30 | Limad Marketing Exp & Imp | Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici. |
| CH683966A5 (it) | 1993-02-19 | 1994-06-30 | Limad Marketing Exp & Imp | Composti della classe dei ftalidrazidici come sostanze attive in agenti anti-ipossici e di difesa. |
| RU2113222C1 (ru) * | 1997-09-30 | 1998-06-20 | Закрытое акционерное общество "Центр современной медицины "Медикор" | Иммуномодулирующее средство |
| RU2138264C1 (ru) | 1999-05-06 | 1999-09-27 | Абидов Муса Тажудинович | Способ получения лекарственного препарата галавит |
| AU4291201A (en) * | 2000-03-28 | 2001-10-08 | Musa Tazhudinovich Abidov | A medicament and method for the production thereof |
| RU2167659C1 (ru) | 2000-08-02 | 2001-05-27 | Закрытое акционерное общество "Центр современной медицины "Медикор" | Способ коррекции иммунной системы живого организма |
| RU2169139C1 (ru) | 2000-08-02 | 2001-06-20 | Закрытое акционерное общество "Центр современной медицины "Медикор" | Способ получения щелочных и щелочноземельных солей 5-амино-2,3-дигидро-1,4-фталазиндиона |
| RU2211036C2 (ru) | 2001-11-20 | 2003-08-27 | Общество с ограниченной ответственностью "Абидофарма" | Лекарственный препарат (варианты) и способ его производства |
| RU2222327C2 (ru) | 2002-03-22 | 2004-01-27 | Общество с ограниченной ответственностью "Абидофарма" | Способ получения лекарственного препарата |
| US7326690B2 (en) | 2002-10-30 | 2008-02-05 | Bach Pharma, Inc. | Modulation of cell fates and activities by phthalazinediones |
| RU2238730C1 (ru) | 2003-02-17 | 2004-10-27 | Абидов Муса Тажудинович | Лекарственный препарат |
| RU2233161C1 (ru) | 2003-04-18 | 2004-07-27 | Общество с ограниченной ответственностью "Абидофарма" | Лекарственный препарат (варианты) и способ его производства |
| CN1217193C (zh) * | 2003-07-30 | 2005-08-31 | 中国药科大学 | 心肌肌钙蛋白鲁米诺化学发光免疫分析检测方法 |
| WO2005012309A1 (en) | 2003-08-04 | 2005-02-10 | Valery Khazhmuratovich Zhilov | Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon |
| PL231885B1 (pl) * | 2009-01-16 | 2019-04-30 | Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia | Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie |
| AU2010210467A1 (en) | 2009-02-06 | 2011-08-18 | Bach Pharma, Inc. | Pharmaceutical grade phthalazinediones, process for their preparation and pharmaceutical compositions containing them |
| JP6061081B2 (ja) | 2010-03-01 | 2017-01-18 | メトリオファーム アーゲー | ５−アミノ−２，３−ジヒドロフタラジン−１，４−ジオンナトリウム塩の結晶形ｉまたはｉｉ、それを含有する医薬品調製物、５−アミノ−２，３−ジヒドロフタラジン−１，４−ジオンナトリウム塩の結晶形ｉの製造方法、および５−アミノ−２，３−ジヒドロフタラジン−１，４−ジオンナトリウム塩の結晶形ｉｉの製造方法 |
-
2011
- 2011-03-01 JP JP2012555335A patent/JP6061081B2/ja active Active
- 2011-03-01 US US13/582,522 patent/US8772294B2/en active Active
- 2011-03-01 CN CN201180011760.7A patent/CN102971300B/zh active Active
- 2011-03-01 RS RSP20140416 patent/RS53492B1/en unknown
- 2011-03-01 CA CA2791327A patent/CA2791327C/en active Active
- 2011-03-01 RU RU2012141274/04A patent/RU2585677C2/ru active
- 2011-03-01 CN CN201610087179.8A patent/CN105859634B/zh active Active
- 2011-03-01 NZ NZ601689A patent/NZ601689A/en unknown
- 2011-03-01 ES ES11710423.2T patent/ES2487221T3/es active Active
- 2011-03-01 EP EP14001134.7A patent/EP2774920A1/de not_active Withdrawn
- 2011-03-01 CN CN201610087203.8A patent/CN105726541A/zh active Pending
- 2011-03-01 PL PL11710423T patent/PL2542535T3/pl unknown
- 2011-03-01 DK DK11710423.2T patent/DK2542535T3/da active
- 2011-03-01 KR KR1020127025234A patent/KR101770011B1/ko active IP Right Grant
- 2011-03-01 SI SI201130233T patent/SI2542535T1/sl unknown
- 2011-03-01 BR BR112012021857-3A patent/BR112012021857B1/pt active IP Right Grant
- 2011-03-01 AU AU2011223226A patent/AU2011223226B2/en active Active
- 2011-03-01 PT PT117104232T patent/PT2542535E/pt unknown
- 2011-03-01 CH CH01123/12A patent/CH704794B1/de not_active IP Right Cessation
- 2011-03-01 EP EP11710423.2A patent/EP2542535B1/de active Active
- 2011-03-01 WO PCT/EP2011/001124 patent/WO2011107295A1/de active Application Filing
-
2012
- 2012-08-20 ZA ZA2012/06264A patent/ZA201206264B/en unknown
- 2012-08-29 IL IL221680A patent/IL221680A/en active IP Right Grant
-
2014
- 2014-04-08 US US14/247,626 patent/US9079863B2/en active Active
- 2014-08-04 CY CY20141100589T patent/CY1115585T1/el unknown
- 2014-08-06 HR HRP20140752AT patent/HRP20140752T1/hr unknown
-
2016
- 2016-06-09 JP JP2016115125A patent/JP6206689B2/ja active Active
- 2016-10-24 HK HK16112165.6A patent/HK1223929A1/zh unknown
- 2016-10-24 HK HK16112162.9A patent/HK1223836A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL221680A0 (en) | Crystalline forms for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said forms | |
| HK1216173A1 (zh) | -芳基取代的和 -雜芳基取代的 -羥基吡啶- -基-羰基氨基-鏈烷酸及其衍生物和其鹽，以及用相應 -羥基吡啶甲酸的衍生物進行製備的方法 | |
| EP2649060A4 (en) | PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES AND THEIR SALTS | |
| EP2659883A4 (en) | MICROCAPSE PREPARATION OF ALGINATCHITOSANACYL DERIVATIVES, MANUFACTURE AND APPLICATION | |
| HK1218709A1 (zh) | 新水楊酸衍生物、其藥學上可接受的鹽、其組合物以及其使用方法 | |
| EP2576576A4 (en) | HETEROCYCLYL-PYRIDINYL BASE PHOSPHONIC ACID, PHARMACEUTICALLY ALLOWED SALT, COMPOSITION, AND METHOD OF USE THEREOF | |
| PL3210991T3 (pl) | Postać krystaliczna lewoizowalerylospiramycyny II oraz preparaty, sposoby wytwarzania i ich zastosowanie | |
| PL2281822T3 (pl) | Nowe pochodne dihydroindolonów, sposób ich wytwarzania i zawierające je kompozycje farmaceutyczne | |
| ZA201500362B (en) | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | |
| EP2660242A4 (en) | CRYSTALLINE FORM OF ERTAPENE-SODIUM AND METHOD OF MANUFACTURING THEREOF | |
| EP2536285A4 (en) | SUBSTITUTED CONDENSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOUNDS AND USER METHOD THEREFOR | |
| EP2709455A4 (en) | PROCESSES FOR THE PREPARATION OF 5-AZASPIRO [2.4] HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES | |
| EP2615099A4 (en) | Aqueous crystals of 2-O-ALPHA-D-GLUCOSYL-L-ASCORBICIC ACID, POWDERY AQUEOUS CRYSTALS FROM 2-O-ALPHA-D-GLUCOSYL-L-ASCORBICIC ACID, METHOD FOR PRODUCING THE AQUEOUS CRYSTALS, METHOD FOR THE PRODUCTION OF THE POWDER, USE OF THE INVENTION AQUEOUS CRYSTALS AND USE OF THE POWDER | |
| PL3586632T3 (pl) | Pochodne 10H-benzo[g]pterydyno-2,4-dionu, sposób ich wytwarzania i ich zastosowanie | |
| IL233199B (en) | History of heterocyclic carboxamides, their preparation and pharmaceutical preparations containing them | |
| EP2398804A4 (en) | ACID ADDITION SALT FROM UDENAFIL, METHOD OF MANUFACTURING THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH | |
| GB2495458B (en) | Crystals of carboprost tromethamine and the preparation method as well as the uses thereof | |
| WO2012018791A3 (en) | Preparation of prasugrel hydrochloride | |
| HUP1000565A2 (en) | Process for the preparation of pharmaceutically active compound and intermediers | |
| EP2725024A4 (en) | AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | |
| IL230907A0 (en) | Salt and formations of a pyrazolopyrimidine compound, a medical composition that includes the above, and a preparation and use process for them | |
| EP2896625A4 (en) | CO-CRYSTAL OF PIPÉRACILLIN SODIUM AND SULBACTAM SODIUM AND PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF | |
| EP2642855A4 (en) | INTERMEDIATE COMPOUNDS AND METHOD FOR THE PREPARATION OF CHINOLIN DERIVATIVES SUCH AS LAQUINIMOD SODIUM | |
| EP2598485A4 (en) | NEW MONTELUKAST 4-HALOGENOBENZYLAMINE SALT AND PROCESS FOR PREPARING MONTELUKAST SODIUM SALT USING THE SAME | |
| WO2013114397A3 (en) | Pharmaceutically acceptable salt of brinzolamide and composition thereof |